The Federal Circuit Says


Inequitable conduct may be found where a patentee knowingly failed to disclose to a USPTO examiner contradictory representations made in another forum with respect to prior art. In Therasense, Inc. v. Becton, Dickinson & Co., Nos. 08-1511, -1512, -1513, 1514, -1595 (Fed. Cir. Jan. 25, 2010), the Federal Circuit found U.S. Patent No. 5,820,551 (“the ’551 patent”), owned by Abbott Diabetes Care, Inc. (Abbott), Therasense, Inc.’s (Therasense) successor, to be unenforceable due to inequitable conduct during prosecution. The ’551 patent related to disposable glucose test strips utilizing electrochemical sensors, and its claims were particularly directed to electrochemical sensors lacking a protective membrane.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Intellectual Property Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Finnegan | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »